Marcia S. Brose

1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

A. Mansfield, G. Curigliano, M. Brose, 2020 .